Progression-free survival (PFS) by independent review results from ALLIANCE A031203 trial (CABOSUN): cabozantinib versus sunitinib as initial targeted therapy for patients (pts) with metastatic renal cell carcinoma (mRCC)
- Citation:
- Ann Oncol vol 28 (suppl 5) mdx440.032, LBA38
- Meeting Instance:
- ESMO 2017
- Year:
- 2017
- Type:
- Abstract
- Sub type:
- Poster Discussion
- Funding:
- NCTN
- Endpoint:
- Primary
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- ppub
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- Yes
- Parents:
- None
- Children:
- 2834
- Pharmas:
- Exelixis
- Grants:
- U10CA180821, U10CA180882
- Corr. Author:
- Authors:
- Toni K. Choueiri Colin Hessel Susan Halabi Ben Sanford Olwen Hahn Olenck T. Michaelson Picus J E.J. Small S. Dakhi George D.J. Scheffold C. M.J. Morris
- Networks:
- CA824, LAPS-IL057, LAPS-MA036, LAPS-NY016
- Study
- Alliance-A031203
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 2
- Keywords: